Cargando…
Clinical characteristics of Japanese patients with moderate to severe COVID-19
INTRODUCTION: Although several reports on the risk factors for severe disease of COVID-19 already exist, reports on effective early indicators are still limited, especially from Japan. This study was conducted to clarify the patient’s characteristics whose disease progressed to severe status. METHOD...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7931728/ https://www.ncbi.nlm.nih.gov/pubmed/33727024 http://dx.doi.org/10.1016/j.jiac.2021.02.028 |
_version_ | 1783660349553115136 |
---|---|
author | Otoshi, Ryota Hagiwara, Eri Kitayama, Takaaki Yamaya, Takafumi Higa, Katsuyuki Murohashi, Kota Sato, Yozo Tabata, Erina Shintani, Ryota Okabayashi, Hiroko Ikeda, Satoshi Niwa, Takashi Nakazawa, Atsuhito Oda, Tsuneyuki Okuda, Ryo Sekine, Akiamasa Kitamura, Hideya Baba, Tomohisa Komatsu, Shigeru Ogura, Takashi |
author_facet | Otoshi, Ryota Hagiwara, Eri Kitayama, Takaaki Yamaya, Takafumi Higa, Katsuyuki Murohashi, Kota Sato, Yozo Tabata, Erina Shintani, Ryota Okabayashi, Hiroko Ikeda, Satoshi Niwa, Takashi Nakazawa, Atsuhito Oda, Tsuneyuki Okuda, Ryo Sekine, Akiamasa Kitamura, Hideya Baba, Tomohisa Komatsu, Shigeru Ogura, Takashi |
author_sort | Otoshi, Ryota |
collection | PubMed |
description | INTRODUCTION: Although several reports on the risk factors for severe disease of COVID-19 already exist, reports on effective early indicators are still limited, especially from Japan. This study was conducted to clarify the patient’s characteristics whose disease progressed to severe status. METHODS: The medical records of all consecutive 300 Japanese patients hospitalized at our institution between February and November 2020 were retrospectively reviewed. The clinical characteristics were evaluated to compare between mild (no oxygen needed), moderate (oxygen needs of 1–4 L/min), and severe diseases (oxygen needs of 5 L/min or more). RESULTS: The median age was 68 years old, with 123 (41.0%) males and 177 (59.0%) females. Of these, 199 patients (66.3%), 55 patients (18.3%), 46 patients (15.3%) patients were in the mild disease, moderate disease, severe disease groups, respectively. Patients with severe disease were more likely to be older, have more comorbidities, and tended to have higher body mass index. In laboratory data, lymphocyte count, levels of C-reactive protein (CRP), LDH, and AST on admission were significantly associated with the severity. In multivariate analysis, age and CRP were the independent risk factors for severe disease (OR = 1.050, 1.130, respectively). The optimal cut-off value for age was 74 years old and that for CRP was 3.15 mg/dL. CONCLUSIONS: Age and CRP were independently associated with disease severity of COVID-19 in multivariate analysis. Additionally, the numbers of underlying disease, lymphocyte count, and inflammatory markers such as LDH and D-dimer may also be related to disease severity. |
format | Online Article Text |
id | pubmed-7931728 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79317282021-03-05 Clinical characteristics of Japanese patients with moderate to severe COVID-19 Otoshi, Ryota Hagiwara, Eri Kitayama, Takaaki Yamaya, Takafumi Higa, Katsuyuki Murohashi, Kota Sato, Yozo Tabata, Erina Shintani, Ryota Okabayashi, Hiroko Ikeda, Satoshi Niwa, Takashi Nakazawa, Atsuhito Oda, Tsuneyuki Okuda, Ryo Sekine, Akiamasa Kitamura, Hideya Baba, Tomohisa Komatsu, Shigeru Ogura, Takashi J Infect Chemother Original Article INTRODUCTION: Although several reports on the risk factors for severe disease of COVID-19 already exist, reports on effective early indicators are still limited, especially from Japan. This study was conducted to clarify the patient’s characteristics whose disease progressed to severe status. METHODS: The medical records of all consecutive 300 Japanese patients hospitalized at our institution between February and November 2020 were retrospectively reviewed. The clinical characteristics were evaluated to compare between mild (no oxygen needed), moderate (oxygen needs of 1–4 L/min), and severe diseases (oxygen needs of 5 L/min or more). RESULTS: The median age was 68 years old, with 123 (41.0%) males and 177 (59.0%) females. Of these, 199 patients (66.3%), 55 patients (18.3%), 46 patients (15.3%) patients were in the mild disease, moderate disease, severe disease groups, respectively. Patients with severe disease were more likely to be older, have more comorbidities, and tended to have higher body mass index. In laboratory data, lymphocyte count, levels of C-reactive protein (CRP), LDH, and AST on admission were significantly associated with the severity. In multivariate analysis, age and CRP were the independent risk factors for severe disease (OR = 1.050, 1.130, respectively). The optimal cut-off value for age was 74 years old and that for CRP was 3.15 mg/dL. CONCLUSIONS: Age and CRP were independently associated with disease severity of COVID-19 in multivariate analysis. Additionally, the numbers of underlying disease, lymphocyte count, and inflammatory markers such as LDH and D-dimer may also be related to disease severity. Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. 2021-06 2021-03-04 /pmc/articles/PMC7931728/ /pubmed/33727024 http://dx.doi.org/10.1016/j.jiac.2021.02.028 Text en © 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Original Article Otoshi, Ryota Hagiwara, Eri Kitayama, Takaaki Yamaya, Takafumi Higa, Katsuyuki Murohashi, Kota Sato, Yozo Tabata, Erina Shintani, Ryota Okabayashi, Hiroko Ikeda, Satoshi Niwa, Takashi Nakazawa, Atsuhito Oda, Tsuneyuki Okuda, Ryo Sekine, Akiamasa Kitamura, Hideya Baba, Tomohisa Komatsu, Shigeru Ogura, Takashi Clinical characteristics of Japanese patients with moderate to severe COVID-19 |
title | Clinical characteristics of Japanese patients with moderate to severe COVID-19 |
title_full | Clinical characteristics of Japanese patients with moderate to severe COVID-19 |
title_fullStr | Clinical characteristics of Japanese patients with moderate to severe COVID-19 |
title_full_unstemmed | Clinical characteristics of Japanese patients with moderate to severe COVID-19 |
title_short | Clinical characteristics of Japanese patients with moderate to severe COVID-19 |
title_sort | clinical characteristics of japanese patients with moderate to severe covid-19 |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7931728/ https://www.ncbi.nlm.nih.gov/pubmed/33727024 http://dx.doi.org/10.1016/j.jiac.2021.02.028 |
work_keys_str_mv | AT otoshiryota clinicalcharacteristicsofjapanesepatientswithmoderatetoseverecovid19 AT hagiwaraeri clinicalcharacteristicsofjapanesepatientswithmoderatetoseverecovid19 AT kitayamatakaaki clinicalcharacteristicsofjapanesepatientswithmoderatetoseverecovid19 AT yamayatakafumi clinicalcharacteristicsofjapanesepatientswithmoderatetoseverecovid19 AT higakatsuyuki clinicalcharacteristicsofjapanesepatientswithmoderatetoseverecovid19 AT murohashikota clinicalcharacteristicsofjapanesepatientswithmoderatetoseverecovid19 AT satoyozo clinicalcharacteristicsofjapanesepatientswithmoderatetoseverecovid19 AT tabataerina clinicalcharacteristicsofjapanesepatientswithmoderatetoseverecovid19 AT shintaniryota clinicalcharacteristicsofjapanesepatientswithmoderatetoseverecovid19 AT okabayashihiroko clinicalcharacteristicsofjapanesepatientswithmoderatetoseverecovid19 AT ikedasatoshi clinicalcharacteristicsofjapanesepatientswithmoderatetoseverecovid19 AT niwatakashi clinicalcharacteristicsofjapanesepatientswithmoderatetoseverecovid19 AT nakazawaatsuhito clinicalcharacteristicsofjapanesepatientswithmoderatetoseverecovid19 AT odatsuneyuki clinicalcharacteristicsofjapanesepatientswithmoderatetoseverecovid19 AT okudaryo clinicalcharacteristicsofjapanesepatientswithmoderatetoseverecovid19 AT sekineakiamasa clinicalcharacteristicsofjapanesepatientswithmoderatetoseverecovid19 AT kitamurahideya clinicalcharacteristicsofjapanesepatientswithmoderatetoseverecovid19 AT babatomohisa clinicalcharacteristicsofjapanesepatientswithmoderatetoseverecovid19 AT komatsushigeru clinicalcharacteristicsofjapanesepatientswithmoderatetoseverecovid19 AT oguratakashi clinicalcharacteristicsofjapanesepatientswithmoderatetoseverecovid19 |